Mr. Rajeev Talwar is the CEO of DLF Ltd. He started his tenure at DLF as the Managing Director in 2009, before taking over the reins in 2015. He is Commissioner cum Secretary (Transport) in Govt. of NCT of Delhi.
Having graduated as an IAS Officer of the 1978 batch, he has worked for over 28 years with organizations such as the Indian Tourism Development Corporation and the Ministry of Home Affairs, Government of India. He has vast experience of policy-making in all the crucial sectors of India’s economy.
He served as a Director of Delhi Financial Corporation Ltd. and Delhi Metro Rail Corporation Ltd. He was an Independent Non-Executive Director of Indraprastha Gas Ltd., from January 21, 2004 to March 19, 2005. He completed his Master’s Degree in History from Bard College and a Bachelor’s Degree from St. Stephen’s College, University of Delhi.
Mr. Ajay Bahl is one of India’s foremost corporate lawyers and a Founding Partner of AZB & Partners. He is a linchpin of AZB’s corporate, M&A, private equity and finance practices. Throughout his career, he has fought for venerable clients like KPMG, Honeywell, HCL, GSK, Havell’s and DLF for various transactional and tax matters. A particular milestone includes the acquisition of the African operations of Zain by the Bharti Group.
Mr. Bahl started his long and esteemed career as a chartered accountant, qualifying in 1978, before becoming a full-fledged lawyer in 1985. One of his most vivid memories was his involvement as an independent expert on behalf of the Indian Government on accounting and tax issues before the International Court of Justice, Hague. He serves as a member for the Board of Governors of the Indian Institute of Corporate Affairs (IICA), and is a member of the Confederation of Indian Industry (CII).
Dr. Syed Saad Mahmood is a pivotal part of the New York Presbyterian Hospital (of Cornell University) Cardiology Division. He is a Harvard-trained specialist in Onco-Cardiology – a new sub-specialty within cardiology focusing on cardiovascular care of cancer patients and cancer survivors. In addition to seeing patients, his research focus is on autonomic dysfunction in breast cancer patients, and on immune checkpoint inhibitors. He has also helped run the STOP-CA randomized clinical trial looking at the effects of atorvastatin on anthracycline mediated cardiomyopathy. Dr. Mahmood’s far-reaching impact in the field has led to him being the recipient of Massachusetts General Hospital’s (of Harvard University) ‘Rising Star in Global Health Service’ Award in 2017.
Mr. Ajay Kumar Vij serves as Non-Executive Director in Dabur Research Foundation, Althea Life Sciences Ltd. and Famy Care Limited. He was formerly the CEO of Dabur Pharma, a fully integrated global pharmaceutical company which he successfully built from the ground up over 13 years into one of the world’s largest specialty oncology groups. He was instrumental in selling the company to European healthcare major Fresenius for over USD $360 million in 2008. He has broad exposure to the Asian healthcare sector and has wide experience in identifying promising business opportunities, developing a growth strategy and implementing profitable exits.
Mr. Vij is a member of the Young Presidents’ Organization (YPO), and holds a MBA and Bachelor degree in Science from Punjab University, Chandigarh, India.
Medical Director & Head – Division of Minimal Invasive Surgery, Kolmet Hospital & Medical Research Centre Pioneers of Laparoscopic Surgery in India, having conducted more than 6000 such procedures in famed career Part of Faculty of Ethicon Endosurgery Training Institute for Minimally Invasive Surgery (Bombay)